marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
Celldex Therapeutics Financial Ratios 2011-2024 | CLDX
Annual Financial Ratios Celldex Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.0 | -0.0 | -0.0 | -0.0 | -0.7 | -0.4 | -3.9 | -2.6 | -6.3 | -16.2 | -25.8 | -7.1 | -4.0 |
P/S |
0.3 | 0.8 | 0.3 | 0.1 | 9.4 | 6.7 | 28.2 | 48.6 | 147.0 | 534.0 | 512.5 | 37.5 | 19.1 |
EPS |
-2.9 | -2.4 | -1.6 | -2.0 | -3.5 | -14.5 | -0.7 | -1.3 | -1.3 | -1.3 | -1.0 | -1.0 | -1.1 |
EV (Enterprise Value) |
3.97 M | -895 K | -12.6 M | -16.7 M | 51.2 M | 71.7 M | 399 M | 405 M | 781 M | 1.92 B | 1.96 B | 425 M | 195 M |
EBITDA per Share |
-3.13 K | -2.4 K | -1.59 K | -2 K | -3.42 | -7.3 | -12.7 | -19.5 | -19.9 | -20.4 | -15.1 | -14.8 | -15.8 |
EV/EBITDA |
0.2 | -5.9 | -0.4 | -0.6 | -3.0 | -2.2 | -5.7 | -15.6 | -24.1 | -7.1 | -4.4 | ||
PEG |
-0.0 | -0.0 | -0.0 | -0.0 | -0.01 | 0.01 | -0.09 | -0.84 | -8.36 | 0.55 | 2.7 | -0.73 | 0.0 |
P/B |
0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.5 | 1.5 | 1.2 | 2.8 | 9.0 | 6.6 | 4.4 | 2.6 |
P/CF |
-0.0 | -0.0 | -0.0 | -0.0 | -0.7 | -0.8 | -3.5 | -2.8 | -7.8 | -18.5 | -29.3 | -8.4 | -4.9 |
ROE % |
-32.95 | -34.43 | -16.81 | -28.55 | -54.11 | -121.86 | -39.36 | -48.42 | -43.85 | -55.79 | -25.50 | -61.73 | -65.19 |
ROA % |
-30.37 | -31.84 | -15.86 | -25.35 | -41.39 | -97.03 | -29.48 | -33.53 | -37.68 | -47.61 | -23.50 | -47.09 | -45.72 |
ROCE % |
-36.01 | -35.33 | -16.98 | -30.26 | -48.99 | -53.35 | -37.98 | -38.18 | -42.15 | -54.77 | -24.93 | -53.85 | -51.91 |
Current Ratio |
12.8 | 13.3 | 17.7 | 8.9 | 5.7 | 7.9 | 5.2 | 5.6 | 9.8 | 8.4 | 15.0 | 4.8 | 3.8 |
DSO |
78.9 | 40.2 | 77.5 | 69.3 | 103.7 | 121.0 | 53.8 | 96.0 | 64.6 | 43.5 | 43.4 | 1.4 | 6.7 |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
4157.4 | 8336.6 | 4153.7 | 2027.6 | - | - | - | - | - | - | 350.8 | 25.2 | 37.4 |
Operating Cycle |
78.9 | 40.2 | 77.5 | 69.3 | - | - | - | - | - | - | 43.4 | 1.4 | 6.7 |
Cash Conversion Cycle |
-4078.5 | -8296.4 | -4076.2 | -1958.3 | - | - | - | - | - | - | -307.4 | -23.8 | -30.7 |
All numbers in USD currency
Quarterly Financial Ratios Celldex Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.64 | -0.54 | -0.56 | - | -0.81 | -0.65 | -0.62 | - | -0.57 | -0.77 | -0.49 | - | -0.45 | -0.34 | -0.42 | -0.55 | -0.36 | -0.5 | -0.73 | -0.64 | -0.75 | -0.84 | -1.4 | -0.81 | -0.66 | -1.67 | -12.61 | -0.42 | -3.05 | -3.42 | -4.19 | -0.3 | -0.29 | -0.32 | -0.35 | -0.33 | -0.32 | -0.33 | -0.33 | -0.36 | -0.31 | -0.32 | -0.33 | -0.27 | -0.29 | -0.24 | -0.23 | -0.27 | -0.25 | -0.23 | -0.27 | -0.29 | -0.27 | -0.27 | -0.31 |
EBITDA per Share |
- | - | -677 | - | - | - | -672 | - | -543 | -745 | -480 | - | -0.41 | -0.3 | -0.4 | - | -0.28 | -0.41 | -0.67 | - | -0.53 | -0.7 | -1.35 | - | -0.45 | -1.72 | -12.7 | - | -0.22 | -0.21 | -0.28 | - | -0.28 | -0.31 | -0.35 | - | -0.31 | -0.32 | -0.33 | - | -0.32 | -0.31 | -0.35 | - | -0.27 | -0.22 | -0.23 | - | -0.22 | -0.21 | -0.25 | - | -0.22 | -0.23 | -0.28 |
ROE % |
-29.18 | -39.33 | -45.92 | -36.20 | -43.95 | -36.20 | -35.07 | -23.41 | -28.09 | -25.02 | -22.49 | -20.54 | -31.00 | -33.11 | -31.04 | -28.55 | -29.20 | -34.55 | -41.81 | -54.11 | -50.58 | -44.28 | -44.98 | -121.86 | -115.91 | -121.23 | -120.09 | -39.36 | -49.90 | -49.90 | -49.85 | -48.42 | -47.52 | -47.39 | -46.51 | -43.85 | -47.61 | -49.86 | -52.06 | -55.79 | -47.65 | -41.62 | -34.21 | -25.50 | -36.15 | -44.60 | -53.04 | -61.73 | -62.71 | -64.15 | -64.66 | -65.19 | -17.13 | -14.89 | -14.64 |
ROA % |
-26.78 | -35.32 | -41.27 | -32.89 | -40.14 | -33.75 | -32.49 | -21.62 | -26.07 | -23.26 | -20.86 | -18.53 | -27.82 | -29.40 | -27.54 | -25.35 | -24.56 | -27.81 | -32.72 | -41.39 | -38.92 | -34.29 | -35.24 | -97.03 | -92.21 | -95.92 | -94.44 | -29.48 | -36.69 | -36.05 | -35.34 | -33.53 | -34.78 | -36.53 | -37.78 | -37.68 | -40.83 | -42.68 | -44.49 | -47.61 | -41.14 | -36.48 | -30.56 | -23.50 | -30.53 | -35.83 | -41.32 | -47.09 | -46.70 | -46.74 | -46.22 | -45.72 | -12.01 | -10.45 | -10.26 |
ROCE % |
-33.88 | -43.96 | -50.24 | -39.40 | -47.42 | -38.73 | -36.73 | -23.83 | -28.60 | -25.35 | -22.75 | -20.71 | -27.56 | -29.64 | -27.70 | -18.42 | -31.02 | -36.77 | -44.37 | -44.71 | -50.97 | -44.63 | -45.20 | -116.33 | -129.85 | -137.11 | -135.75 | -40.61 | -51.91 | -49.69 | -49.65 | -36.94 | -48.10 | -47.96 | -47.06 | -33.13 | -47.46 | -50.64 | -52.84 | -42.70 | -49.98 | -42.92 | -35.26 | -18.55 | -33.95 | -42.08 | -50.33 | -43.36 | -60.06 | -61.36 | -61.66 | -45.13 | -16.70 | -14.38 | -14.05 |
Current Ratio |
22.1 | 26.5 | 28.7 | 12.8 | 8.4 | 13.8 | 14.9 | 13.3 | 15.5 | 10.6 | 16.4 | 17.7 | 19.6 | 9.2 | 8.8 | 8.9 | 8.9 | 8.9 | 8.9 | 4.2 | 4.2 | 4.2 | 4.2 | 4.9 | 4.9 | 4.9 | 4.9 | 4.0 | 4.0 | 4.0 | 4.0 | 3.2 | 3.2 | 3.2 | 3.2 | 7.1 | 7.1 | 7.1 | 7.1 | 6.8 | 6.8 | 6.8 | 6.8 | 12.7 | 12.7 | 12.7 | 12.7 | 4.2 | 4.2 | 4.2 | 4.2 | 3.4 | 3.4 | 3.4 | 3.4 |
DSO |
34.1 | 76.8 | 1549.8 | - | 11.1 | 243.8 | 78.4 | - | 32.1 | 95.2 | 108.8 | - | 206.7 | 30.5 | 241.8 | 43.4 | 246.2 | 696.8 | 47.1 | 104.4 | 169.6 | 129.5 | 133.7 | 163.6 | 306.6 | 104.4 | 56.5 | 49.6 | 43.7 | 44.8 | 109.0 | 86.9 | 73.3 | 117.2 | 96.4 | 49.5 | 86.3 | 40.6 | 131.2 | 26.4 | 35.4 | 65.8 | 100.5 | 72.0 | 45.5 | 460.0 | 10.1 | 1.1 | 1.3 | 2.0 | 4.0 | 6.4 | 6.6 | 8.0 | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
34.1 | 76.8 | 1549.8 | - | 11.1 | 243.8 | 78.4 | - | 32.1 | 95.2 | 108.8 | - | 206.7 | 30.5 | 241.8 | 43.4 | 246.2 | 696.8 | 47.1 | 104.4 | 169.6 | 129.5 | 133.7 | 163.6 | 306.6 | 104.4 | 56.5 | 49.6 | 43.7 | 44.8 | 109.0 | 86.9 | 73.3 | 117.2 | 96.4 | 49.5 | 86.3 | 40.6 | 131.2 | 26.4 | 35.4 | 65.8 | 100.5 | 72.0 | 45.5 | 460.0 | 10.1 | 1.1 | 1.3 | 2.0 | 4.0 | 6.4 | 6.6 | 8.0 | - |
Cash Conversion Cycle |
34.1 | 76.8 | 1549.8 | - | 11.1 | 243.8 | 78.4 | - | 32.1 | 95.2 | 108.8 | - | 206.7 | 30.5 | 241.8 | 43.4 | 246.2 | 696.8 | 47.1 | 104.4 | 169.6 | 129.5 | 133.7 | 163.6 | 306.6 | 104.4 | 56.5 | 49.6 | 43.7 | 44.8 | 109.0 | 86.9 | 73.3 | 117.2 | 96.4 | 49.5 | 86.3 | 40.6 | 131.2 | 26.4 | 35.4 | 65.8 | 100.5 | 72.0 | 45.5 | 460.0 | 10.1 | 1.1 | 1.3 | 2.0 | 4.0 | 6.4 | 6.6 | 8.0 | - |
All numbers in USD currency